Mirati Therapeutics, Inc. (MRTX) Receives Average Rating of “Hold” from Analysts

Mirati Therapeutics, Inc. (NASDAQ:MRTX) has been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.10.

A number of analysts recently commented on the stock. Jefferies Group LLC reissued a “hold” rating and set a $5.50 price objective on shares of Mirati Therapeutics in a report on Wednesday, April 12th. Zacks Investment Research raised shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Wednesday, May 3rd. Finally, ValuEngine raised shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th.

Shares of Mirati Therapeutics (NASDAQ MRTX) opened at 4.35 on Tuesday. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $7.22. The stock’s market capitalization is $108.48 million. The firm’s 50-day moving average price is $3.36 and its 200 day moving average price is $4.73.

Institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. purchased a new position in Mirati Therapeutics during the first quarter worth $106,000. Trexquant Investment LP raised its position in shares of Mirati Therapeutics by 21.1% in the fourth quarter. Trexquant Investment LP now owns 26,432 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 4,599 shares during the period. Bank of New York Mellon Corp raised its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 11,753 shares during the period. Omega Advisors Inc. bought a new position in shares of Mirati Therapeutics during the first quarter valued at approximately $520,000. Finally, RTW Investments LP raised its position in shares of Mirati Therapeutics by 0.4% in the fourth quarter. RTW Investments LP now owns 129,697 shares of the biotechnology company’s stock valued at $616,000 after buying an additional 568 shares during the period. 64.60% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Mirati Therapeutics, Inc. (MRTX) Receives Average Rating of “Hold” from Analysts” was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.thestockobserver.com/2017/07/18/mirati-therapeutics-inc-mrtx-receives-average-recommendation-of-hold-from-brokerages-updated-updated-updated.html.

Mirati Therapeutics Company Profile

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply